These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 12459380

  • 1. Combination of vascular targeting agents with thermal or radiation therapy.
    Horsman MR, Murata R.
    Int J Radiat Oncol Biol Phys; 2002 Dec 01; 54(5):1518-23. PubMed ID: 12459380
    [Abstract] [Full Text] [Related]

  • 2. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R, Horsman MR.
    Int J Hyperthermia; 2004 Jun 01; 20(4):393-404. PubMed ID: 15204520
    [Abstract] [Full Text] [Related]

  • 3. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy.
    Murata R, Overgaard J, Horsman MR.
    Int J Radiat Oncol Biol Phys; 2001 Nov 15; 51(4):1018-24. PubMed ID: 11704326
    [Abstract] [Full Text] [Related]

  • 4. Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.
    Kragh M, Quistorff B, Horsman MR, Kristjansen PE.
    Neoplasia; 2002 Nov 15; 4(3):263-7. PubMed ID: 11988846
    [Abstract] [Full Text] [Related]

  • 5. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation.
    Horsman MR, Murata R, Overgaard J.
    Acta Oncol; 2001 Nov 15; 40(4):497-503. PubMed ID: 11504310
    [Abstract] [Full Text] [Related]

  • 6. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
    Murata R, Siemann DW, Overgaard J, Horsman MR.
    Radiat Res; 2001 Nov 15; 156(5 Pt 1):503-9. PubMed ID: 11604063
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R, Overgaard J, Horsman MR.
    Int J Hyperthermia; 2001 Nov 15; 17(6):508-19. PubMed ID: 11719967
    [Abstract] [Full Text] [Related]

  • 8. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
    Murata R, Overgaard J, Horsman MR.
    Int J Radiat Biol; 2001 Feb 15; 77(2):195-204. PubMed ID: 11236926
    [Abstract] [Full Text] [Related]

  • 9. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
    Murata R, Siemann DW, Overgaard J, Horsman MR.
    Radiother Oncol; 2001 Aug 15; 60(2):155-61. PubMed ID: 11439210
    [Abstract] [Full Text] [Related]

  • 10. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
    Hokland SL, Horsman MR.
    Int J Hyperthermia; 2007 Nov 15; 23(7):599-606. PubMed ID: 18038290
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation.
    Horsman MR.
    Int J Hyperthermia; 2015 Nov 15; 31(5):453-9. PubMed ID: 25915829
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Wilson WR, Li AE, Cowan DS, Siim BG.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):905-8. PubMed ID: 9845119
    [Abstract] [Full Text] [Related]

  • 13. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
    Nielsen T, Murata R, Maxwell RJ, Stødkilde-Jørgensen H, Ostergaard L, Horsman MR.
    Int J Radiat Oncol Biol Phys; 2008 Mar 01; 70(3):859-66. PubMed ID: 18164835
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.
    Horsman MR, Murata R.
    Int J Radiat Oncol Biol Phys; 2003 Nov 15; 57(4):1047-55. PubMed ID: 14575836
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
    Iversen AB, Busk M, Horsman MR.
    Acta Oncol; 2013 Oct 15; 52(7):1320-6. PubMed ID: 23988183
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.